PMID- 27294846
OWN - NLM
STAT- MEDLINE
DCOM- 20180129
LR  - 20181202
IS  - 1613-6829 (Electronic)
IS  - 1613-6810 (Print)
IS  - 1613-6810 (Linking)
VI  - 12
IP  - 28
DP  - 2016 Jul
TI  - Multifunctional Transmembrane Protein Ligands for Cell-Specific Targeting of 
      Plasma Membrane-Derived Vesicles.
PG  - 3837-48
LID - 10.1002/smll.201600493 [doi]
AB  - Liposomes and nanoparticles that bind selectively to cell-surface receptors can 
      target specific populations of cells. However, chemical conjugation of ligands to 
      these particles is difficult to control, frequently limiting ligand uniformity 
      and complexity. In contrast, the surfaces of living cells are decorated with 
      highly uniform populations of sophisticated transmembrane proteins. Toward 
      harnessing cellular capabilities, here it is demonstrated that plasma membrane 
      vesicles (PMVs) derived from donor cells can display engineered transmembrane 
      protein ligands that precisely target cells on the basis of receptor expression. 
      These multifunctional targeting proteins incorporate (i) a protein ligand, (ii) 
      an intrinsically disordered protein spacer to make the ligand sterically 
      accessible, and (iii) a fluorescent protein domain that enables quantification of 
      the ligand density on the PMV surface. PMVs that display targeting proteins with 
      affinity for the epidermal growth factor receptor (EGFR) bind at increasing 
      concentrations to breast cancer cells that express increasing levels of EGFR. 
      Further, as an example of the generality of this approach, PMVs expressing a 
      single-domain antibody against green fluorescence protein (eGFP) bind to cells 
      expressing eGFP-tagged receptors with a selectivity of  approximately 50:1. The results 
      demonstrate the versatility of PMVs as cell targeting systems, suggesting diverse 
      applications from drug delivery to tissue engineering.
CI  - (c) 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
FAU - Zhao, Chi
AU  - Zhao C
AD  - Department of Biomedical Engineering, Institute for Cellular and Molecular 
      Biology, The University of Texas at Austin, TX, 78712, USA.
FAU - Busch, David J
AU  - Busch DJ
AD  - Department of Biomedical Engineering, Institute for Cellular and Molecular 
      Biology, The University of Texas at Austin, TX, 78712, USA.
FAU - Vershel, Connor P
AU  - Vershel CP
AD  - Department of Biomedical Engineering, Institute for Cellular and Molecular 
      Biology, The University of Texas at Austin, TX, 78712, USA.
FAU - Stachowiak, Jeanne C
AU  - Stachowiak JC
AD  - Department of Biomedical Engineering, Institute for Cellular and Molecular 
      Biology, The University of Texas at Austin, TX, 78712, USA.
LA  - eng
GR  - R01 GM112065/GM/NIGMS NIH HHS/United States
PT  - Journal Article
DEP - 20160613
PL  - Germany
TA  - Small
JT  - Small (Weinheim an der Bergstrasse, Germany)
JID - 101235338
RN  - 0 (Liposomes)
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - Animals
MH  - CHO Cells
MH  - Cell Line, Tumor
MH  - Cell Membrane/*chemistry/*metabolism
MH  - Cricetulus
MH  - Drug Delivery Systems
MH  - ErbB Receptors/chemistry
MH  - Humans
MH  - Liposomes/chemistry
MH  - Tissue Engineering
PMC - PMC5523125
MID - NIHMS880840
OTO - NOTNLM
OT  - biomaterials
OT  - cell targeting
OT  - extracellular vesicles
OT  - protein engineering
EDAT- 2016/06/14 06:00
MHDA- 2018/01/30 06:00
PMCR- 2017/07/24
CRDT- 2016/06/14 06:00
PHST- 2016/02/15 00:00 [received]
PHST- 2016/04/18 00:00 [revised]
PHST- 2016/06/14 06:00 [entrez]
PHST- 2016/06/14 06:00 [pubmed]
PHST- 2018/01/30 06:00 [medline]
PHST- 2017/07/24 00:00 [pmc-release]
AID - 10.1002/smll.201600493 [doi]
PST - ppublish
SO  - Small. 2016 Jul;12(28):3837-48. doi: 10.1002/smll.201600493. Epub 2016 Jun 13.